Status:
COMPLETED
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Lead Sponsor:
Bayer
Conditions:
Ophthalmology, Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between Jan...
Eligibility Criteria
Inclusion
- Diagnosis of wet age-related macular degeneration
- Start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab between January 1, 2009 and August 31, 2009
- Informed consent form signed, where required
Exclusion
- Participation in an investigational study during anti-VEGF therapy (from start up to August 31, 2011) that involved treatment with any drug or medical device
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
2609 Patients enrolled
Trial Details
Trial ID
NCT01447043
Start Date
January 1 2009
End Date
November 1 2012
Last Update
January 27 2014
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Australia
2
Many Locations, Canada
3
Many Locations, France
4
Many Locations, Germany